Skip to main
RNTX

RNTX Stock Forecast & Price Target

RNTX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rein Therapeutics is a promising biopharmaceutical company with a solid pipeline of potential treatments for orphan pulmonary and fibrosis indications. The recent updates and financing have significantly reduced the company's risk and granted it a clearer path towards the Phase 2 readout of its lead candidate, LTI-03. With its unique mechanism of action targeting both fibrotic signaling and epithelial repair, LTI-03 has the potential to be a differentiated IPF asset, with a favorable risk-reward from current levels. However, risks to the company's forecasts and thesis include financing, development, and regulatory risks.

Bears say

Rein Therapeutics is quickly moving towards the end of its Phase 2 trial for its lead candidate LTI-03, but with no approved treatments for the targeted indications, there is a high risk that the trial will not show meaningful clinical benefit. Additionally, while the recent financing may provide enough funding for the trial to be completed, the dilution caused by the oversubscribed offering could potentially limit future upside for the stock. Overall, the company's high reliance on LTI-03 and lack of a diversified pipeline make it a risky investment option.

RNTX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rein Therapeutics Inc (RNTX) Forecast

Analysts have given RNTX a Strong Buy based on their latest research and market trends.

According to 2 analysts, RNTX has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rein Therapeutics Inc (RNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.